1.1. Analysis.
Comparison 1: Nirmatrelvir/ritonavir for treating COVID‐19 in outpatient settings with asymptomatic or mild disease , Outcome 1: All‐cause mortality at day 28
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.